CellVoyant

📍 Bristol, United Kingdom🗓 Founded 2021👥 12 employees💰 Last funded Oct 2023
Biotechnology🌐 cellvoyant.com
Website LinkedIn
CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol. We’re working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world. Our mission is bold and ambitious and we have the best investors behind us from day 1. We’re backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We’re also supported by the founder/CEO of Abcam, which pioneered the antibody business.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in CellVoyant?
CellVoyant has 1 investors on record on gritt.io, including 1 early-stage backers.
When did CellVoyant last raise funding?
The most recent investment in CellVoyant recorded on gritt.io was in October 2023.
When was CellVoyant founded?
CellVoyant was founded in 2021.
What industry is CellVoyant in?
CellVoyant operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is CellVoyant based?
CellVoyant is headquartered in Bristol, United Kingdom.